Institute of Neurophysiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Pharmacological and Drug Safety Research, Gedeon Richter Plc, Budapest, Hungary.
Br J Pharmacol. 2020 Apr;177(7):1622-1634. doi: 10.1111/bph.14923. Epub 2020 Feb 19.
Gamma oscillations are fast rhythmic fluctuations of neuronal network activity ranging from 30 to 90 Hz that establish a precise temporal background for cognitive processes such as perception, sensory processing, learning, and memory. Alterations of gamma oscillations have been observed in schizophrenia and are suggested to play crucial roles in the generation of positive, negative, and cognitive symptoms of the disease.
In this study, we investigated the effects of the novel antipsychotic cariprazine, a D -preferring dopamine D /D receptor partial agonist, on cholinergically induced gamma oscillations in rat hippocampal slices from treatment-naïve and MK-801-treated rats, a model of acute first-episode schizophrenia.
The D receptor-preferring agonist pramipexole effectively decreased the power of gamma oscillations, while the D receptor antagonist SB-277011 had no effect. In treatment-naïve animals, cariprazine did not modulate strong gamma oscillations but slightly improved the periodicity of non-saturated gamma activity. Cariprazine showed a clear partial agonistic profile at D receptors at the network level by potentiating the inhibitory effects when the D receptor tone was low and antagonizing the effects when the tone was high. In hippocampal slices of MK-801-treated rats, cariprazine allowed stabilization of the aberrant increase in gamma oscillation power and potentiated resynchronization of the oscillations.
Data from this study indicate that cariprazine stabilizes pathological hippocampal gamma oscillations, presumably by its partial agonistic profile. The results demonstrate in vitro gamma oscillations as predictive biomarkers to study the effects of antipsychotics preclinically at the network level.
伽马振荡是神经元网络活动的快速节律性波动,频率范围为 30 至 90 Hz,为感知、感觉处理、学习和记忆等认知过程建立精确的时间背景。精神分裂症中观察到伽马振荡的改变,并被认为在疾病阳性、阴性和认知症状的产生中起关键作用。
在这项研究中,我们研究了新型抗精神病药卡利拉嗪(一种 D 型优先多巴胺 D / D 受体部分激动剂)对未经治疗和 MK-801 治疗的大鼠海马切片中胆碱能诱导的伽马振荡的影响,MK-801 是急性首发精神分裂症的模型。
D 型受体优先激动剂普拉克索有效降低了伽马振荡的功率,而 D 型受体拮抗剂 SB-277011 则没有作用。在未经治疗的动物中,卡利拉嗪不会调节强伽马振荡,但会略微改善非饱和伽马活动的周期性。卡利拉嗪在网络水平上对 D 受体表现出明显的部分激动剂特征,即在 D 受体调谐低时增强抑制作用,在调谐高时拮抗作用。在 MK-801 治疗的大鼠海马切片中,卡利拉嗪允许稳定异常增加的伽马振荡功率,并增强振荡的重新同步。
本研究数据表明,卡利拉嗪通过其部分激动剂特征稳定病理性海马伽马振荡。结果表明,在体外伽马振荡作为预测生物标志物,可在网络水平上对抗精神病药的临床前效果进行研究。